Tevimbra

News

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

Akeso/Summit's PD-1xVEGF drug ivonescimab bests a PD-1 inhibitor as first-line therapy in Chinese NSCLC patients, but a bigger test is yet to come.

News

BeiGene abandons TIGIT antibody after lung cancer flop

BeiGene has decided to stop the development of its TIGIT-targeting drug ociperlimab in yet another setback for the drug class.

News

EU OK sets up first ex-China launches for BeiGene's Tevimbra

BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside

ESMO: Ivonescimab beats BeOne PD-1 in first-line lung cancer

BeiGene abandons TIGIT antibody after lung cancer flop

EU OK sets up first ex-China launches for BeiGene's Tevimbra

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks